The first head-to-head test of two blockbuster weight-loss drugs has shown that silent is more effective than rival vegovi.

Both drugs lost weight due to trial, but after 72 weeks of treatment, after 72 weeks of treatment, a 20% weight reduction of Munjaro increased to more than 14% from the Vegovi.

Researchers leading the trial said that both drugs had a role, but silence can help those who can help lose weight the most.

Both drugs make you feel full so that you eat less and burn the body fat instead – but how they work to explain the difference in effectiveness, the subtle difference in it.

Wagovi, also known as semaglutide, mimics a hormone released by the body after meals to flip a hunger switch in the brain. Mounjaro, or Tirzepatide, does two flip.

The case, which was paid by Eli Lily, the creator of Maunjaro, included 750 thick people, with an average weight 113 kg (about 18 stones).

They were asked to take the highest dosage that they could tolerate one of the two drugs.

The conclusions presented in the European Congress on obesity in Malaga and New England Journal of Medicine showed:

• 32% of people lost a quarter of their body weight on the vegovi compared to 16%
• The people of Mounjaro lost an average of 18 cm from their waist compared to 13 cm on the vegovi.
• Mounjaro had better blood pressure, blood sugar and cholesterol levels on Mounjaro.
• Both had similar levels as side-effects.
• Women lost overweight than men.

Dr. who tested the Wide Weight Control Center at Weel Cornell Medicine in New York. Luis Aaron said: “Most obese people will fix with Semglatide (vegovi), in high end they can eventually improve with tirzepetides (Maunjaro).”

In the UK, two drugs are available from expert weight-management services, but it can also be purchased privately.

Prof. Neveda Sattar of the University of Glasgow said that drugs were “good options” for patients, but “Many people would be satisfied with 15% weight loss … many want to lose more weight”.

He said, “In the UK, the sales of the tirzepetide are now ahead of semaglutide now – this is just a reality – and it will accelerate the paper that I imagine,” he said.

However, Wagovi is also licensed for other situations – such as stopping a heart attack – while the same test with foggy is not completed.

• Weight-loss drug approved for heart problems in UK

A large amount of research is still being done in weight loss drugs. High doses of current drugs are being tested, as new methods of taking them such as oral pills and new drugs that function in different ways on the body are being investigated.

This means that the final winner in the region has not yet been determined.

Prof. Sattar says that the amount of research means that we can reach the point where “prevention of obesity may also be possible soon”, but the argument is “it would be better” to prevent people from getting healthy to make our society healthy.